-
Mashup Score: 24
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 64Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM - Full Text View - ClinicalTrials.gov - 2 month(s) ago
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 9
TN-201 gene therapy is being studied in the Phase 1b MyPeak-1™ clinical trial for the treatment of genetic hypertrophic cardiomyopathy caused by variations i…
Source: www.youtube.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 11Alzheimer’s Disease: Developing Drugs for Treatment Guidance - 2 month(s) ago
Clincal / Medical
Source: www.fda.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 76Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week - 2 month(s) ago
AbstractCardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly effective specific therapies have recently become available for the 2 most frequent forms of card…
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3
MicroRNA-21 (miR-21) plays a significant role in the regulation of fibrotic and inflammatory gene expression signatures. Endogenous miR-21 shows robust expressi
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM - 2 month(s) ago
– BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe – BridgeBio to receive royalties according to a tiered structure beginning in the low-thirties percent, designed to provide BridgeBio the opportunity to maximally share in the blockbuster potential of acoramidis – BridgeBio will also receive up to $310 Million USD in upfront and near-term milestone payments, and is eligible for additiona
Source: finance.yahoo.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma - 2 month(s) ago
Simon and colleagues discovered that a small interfering RNA (siRNA) that inhibits the fusion kinase DNAJB1:PRKACA drives fibrolamellar hepatocellular carcinoma (FLC). Using the asialoglycoprotein receptor, siRNA could be effectively delivered to FLC cells, inhibiting tumor growth in patient-derived xenografts, demonstrating its potential as a treatment option for FLC patients.
Source: www.cell.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1Pass a Ban on Physician Non-Competes in Oregon! - 2 month(s) ago
Dear OR-ACC Member-HB 4130 seeks to ban non-compete agreements for physicians in Oregon, regardless of income. Non-compete agreements restrict how and where a physician may practice after leaving employment and limit their contact with existing…
Source: www.votervoice.netCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review - 3 month(s) ago
Abstract Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of cardiomyopathy are common presenting features, and patients often are referred to cardiologis…
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet
First patient is in MAGNITUDE We are gearing up to start the trial soon as well #transthyretin #amyloidosis #CardioTwitter https://t.co/npJlvcrrkM